Literature DB >> 2901920

Effect of in vitro organic nitrate tolerance on relaxation, cyclic GMP accumulation, and guanylate cyclase activation by glyceryl trinitrate and the enantiomers of isoidide dinitrate.

B M Bennett1, H Schröder, L D Hayward, S A Waldman, F Murad.   

Abstract

Previously, it was shown that the D enantiomer of isoidide dinitrate was 10-fold more potent than the L enantiomer and 10-fold less potent than glyceryl trinitrate for stimulating cyclic GMP accumulation and relaxation of isolated rat aorta. In the present study, these organic nitrates were tested for their ability to induce tolerance to organic nitrate-induced relaxation, cyclic GMP accumulation, and guanylate cyclase activation in rat aorta in vitro. To compensate for the differences in vasodilator potency, tolerance was induced by incubating isolated rat aorta with concentrations of organic nitrates 1,000-fold greater than the EC50 for relaxation. Under these conditions, the EC50 for relaxation was increased significantly for each organic nitrate and to a similar degree on subsequent reexposure. These data suggest that the potential for inducing in vitro tolerance to relaxation was the same for the three organic nitrates tested. When activation of soluble guanylate cyclase by these compounds was assessed, the enantiomers of isoidide dinitrate were equipotent, but less potent than glyceryl trinitrate, suggesting that the site of enantioselectivity is not guanylate cyclase itself. In blood vessels made tolerant to organic nitrates by pretreatment with glyceryl trinitrate, vasodilator activity, cyclic GMP accumulation, and guanylate cyclase activation were attenuated on reexposure to each organic nitrate. In addition, differences in the potency of the three organic nitrates and the enantioselectivity of isoidide dinitrate for relaxation were abolished in tolerant tissue, whereas the potency difference between glyceryl trinitrate and isoidide dinitrate for activation of guanylate cyclase was unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901920     DOI: 10.1161/01.res.63.4.693

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  8 in total

1.  Characterization of furoxans as a new class of tolerance-resistant nitrovasodilators.

Authors:  M Hecker; W Vorhoff; A T Bara; P I Mordvintcev; R Busse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

2.  Effect of overexpression of human aldehyde dehydrogenase 2 in LLC-PK1 cells on glyceryl trinitrate biotransformation and cGMP accumulation.

Authors:  Y D'Souza; Y Ji; B M Bennett
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

3.  Enantioselective inhibition of the biotransformation and pharmacological actions of isoidide dinitrate by diphenyleneiodonium sulphate.

Authors:  J D Ratz; J J McGuire; B M Bennett
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

4.  Heme oxygenase-1 deficiency leads to alteration of soluble guanylate cyclase redox regulation.

Authors:  Allan W Jones; William Durante; Ronald J Korthuis
Journal:  J Pharmacol Exp Ther       Date:  2010-07-06       Impact factor: 4.030

Review 5.  Mechanisms of action of nitrates.

Authors:  K E Torfgård; J Ahlner
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 6.  Homocysteine in renovascular complications: hydrogen sulfide is a modulator and plausible anaerobic ATP generator.

Authors:  Utpal Sen; Sathnur B Pushpakumar; Matthew A Amin; Suresh C Tyagi
Journal:  Nitric Oxide       Date:  2014-06-22       Impact factor: 4.427

Review 7.  Endothelial nitric oxide synthase-derived nitric oxide in the regulation of metabolism.

Authors:  Margarita Tenopoulou; Paschalis-Thomas Doulias
Journal:  F1000Res       Date:  2020-10-01

Review 8.  Vascular system: role of nitric oxide in cardiovascular diseases.

Authors:  Ka Bian; Marie-Françoise Doursout; Ferid Murad
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-04       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.